Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment

Critical Reviews in Oncology/Hematology

Volumn 62, Issue 1, 2007, Pages 34-42

  Loisel, Severine ^a   Ohresser, Marc ^b   Pallardy, Marc ^c   Daydé, David ^b   Berthou, Christian ^a   Cartron, Guillaume ^b   Watier, Hervé ^b,d  

^a Universite de Brest   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Animal models; Cross reactivity; Fc R; Immunogenicity; Monoclonal antibodies; Pharmacodynamics; Pharmacokinetics; Preclinical studies; Toxicity

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CETUXIMAB; EFALIZUMAB; FC RECEPTOR; INFLIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; RITUXIMAB; TGN 1412; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BLEEDING; CANCER; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CROSS REACTION; DRUG DISTRIBUTION; EFFECTOR CELL; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOGENICITY; NONHUMAN; PRIMATE; REVIEW; RODENT; THROMBOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS;

EID: 33847250889     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.11.010     Document Type: Review

References (58)

1. Predki P.F., Mattoon D., Bangham R., Schweitzer B., and Michaud G. Protein microarrays: a new tool for profiling antibody cross-reactivity. Hum Antibodies 14 1-2 (2005) 7-15
2. Vugmeyster Y., Howell K., Bakshl A., Flores C., and Canova-Davis E. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A 52 (2003) 101-109
3. Schroder C., Azimzadeh A.M., Wu G., Price J.O., Atkinson J.B., and Pierson R.N. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transplant Immunol 12 1 (2003) 19-28
4. McCauley T.C., Kurth B.E., Norton E.J., Klotz K.L., Westbrook V.A., Rao A.J., et al. Analysis of a human sperm CD52 glycoform in primates: identification of an animal model for immunocontraceptive vaccine development. Biol Reprod 66 6 (2002) 1681-1688
5. Perry A.C., Jones R., and Hall L. Identification of an abundant monkey epididymal transcript encoding a homologue of human CAMPATH-1 antigen precursor. Biochim Biophys Acta 1171 1 (1992) 122-124
6. Hale G., Swirsky D.M., Hayhoe F.G., and Waldmann H. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1 3 (1983) 321-334
7. http://www.emea.eu.int/humandocs/Humans/EPAR/herceptin/herceptin.htm
8. http://www.emea.eu.int/humandocs/Humans/EPAR/erbitux/erbitux.htm
9. Ryan A.M., Eppler D.B., Hagler K.E., Bruner R.H., Thomford P.J., Hall R.L., et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27 1 (1999) 78-86
10. Uchida J., Hamaguchi Y., Oliver J.A., Ravetch J.V., Poe J.C., Haas K.M., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199 12 (2004) 1659-1669
11. Garrido G., Sanchez B., Rodriguez H.M., Lorenzano P., Alonso D., and Fernandez L.E. 7A7 MAb: a new tool for the preclinical evaluation of EGFR-based therapies. Hybrid Hybridomics 23 3 (2004) 168-175
12. Clarke J., Leach W., Pippig S., Joshi A., Wu B., House R., et al. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul Toxicol Pharmacol 40 3 (2004) 219-226
13. Tedder TF, Baras A, Xiu Y. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol 2006, November 8 [Epub ahead of print].
14. Beyersdorf N., Gaupp S., Balbach K., Schmidt J., Toyka K.V., Lin C.H., et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 202 3 (2005) 445-455
15. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 10 (2006) 1018-1028
16. Golay J., Cittera E., Di Gaetano N., Manganini M., Mosca M., Nebuloni M., et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 91 2 (2006) 176-183
17. Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171 3 (2003) 1581-1587
18. Clarke P., Mann J., Simpson J.F., Rickard-Dickson K., and Primus F.J. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 58 7 (1998) 1469-1477
19. Eades-Perner A.M., and Zimmermann W. Carcinoembryonic antigen-transgenic mice: a model for tumor immunotherapy. Tumour Biol 16 1 (1995) 56-61
20. Horig H., Wainstein A., Long L., Kahn D., Soni S., Marcus A., et al. A new mouse model for evaluating the immunotherapy of human colorectal cancer. Cancer Res 61 23 (2001) 8520-8526
21. Wilkinson R.W., Ross E.L., Poulsom R., Ilyas M., Straub J., Snary D., et al. Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors. Proc Natl Acad Sci USA 98 18 (2001) 10256-10260
22. Xu X., Clarke P., Szalai G., Shively J.E., Williams L.E., Shyr Y., et al. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 60 16 (2000) 4475-4484
23. Thompson J.A., Eades-Perner A.M., Ditter M., Muller W.J., and Zimmermann W. Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy. Int J Cancer 72 1 (1997) 197-202
24. Benson A.B., Catalano P.J., Meropol N.J., et al. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the eastern cooperative oncology group (ECOG) study ES3200. Proc Am Soc Clin Oncol 22 (2003) 243 [abstract 975]
25. Suter T.M., Cook-Bruns N., and Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13 3 (2004) 173-183
26. Keefe D.L. Trastuzumab-associated cardiotoxicity. Cancer 95 7 (2002) 1592-1600 [Erratum in: Cancer 2003;97(4):1136]
27. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 2 (1994) 435-445
28. http://www.emea.eu.int/humandocs/PDFs/EPAR/mabcampath/130101en6.pdf
29. Fishwild D.M., Hudson D.V., Deshpande U., and Kung A.H. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. Clin Immunol 92 2 (1999) 138-152
30. Springer T.A., Bhattacharya A., Cardoza J.T., and Sanchez-Madrid F. Monoclonal antibodies specific for rat IgG1, IgG2a, and IgG2b subclasses, and kappa chain monotypic and allotypic determinants: reagents for use with rat monoclonal antibodies. Hybridoma 1 3 (1982) 257-273
31. Sarnesto A., Ranta S., Seppala I.J., and Makela O. Relative immunogenicity in mice of different regions of the human IgG. Scand J Immunol 17 6 (1983) 507-511
32. Nik Jaafar M.I., Lowe J.A., Ling N.R., and Jefferis R. Immunogenic and antigenic epitopes of immunoglobulins. VII. The topographical distribution of Fc gamma epitopes and the relationship of an iso-allotypic specificity to the presence of histidine 435. Mol Immunol 21 2 (1984) 137-143
33. Ling N.R., Elliott D., and Lowe J. Modulation of the murine immune response to human IgG by complexing with monoclonal antibodies. I. Antibody responses to determinants on the constant region of light chains and gamma chains. Immunology 62 1 (1987) 1-6
34. Silvestris F., Rots N., Yancey Jr. W.B., Malone C., Searles R., Solomon A., et al. Monoclonal antibodies against human anti-F(ab′)2 antibodies react with light chain epitopes. Clin Immunol Immunopathol 59 1 (1991) 139-155
35. Chiller J.M., and Weigle W.O. Termination of tolerance to human gamma globulin in mice by antigen and bacterial lipopolysaccharide (endotoxin). J Exp Med 137 3 (1973) 740-750
36. Parks D.E., Walker S.M., and Weigle W.O. Bacterial lipopolysaccharide (endotoxin) interferes with the induction of tolerance and primes thymus-derived lymphocytes. J Immunol 126 3 (1981) 938-942
37. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 7 (2003) 601-608
38. Weinberg W.C., Frazier-Jessen M.R., Wu W.J., Weir A., Hartsough M., Keegan P., et al. Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev 24 4 (2005) 569-584
39. Ober R.J., Martinez C., Vaccaro C., Zhou J., and Ward E.S. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 172 4 (2004) 2021-2029
40. Roopenian D.C., Christianson G.J., Sproule T.J., Brown A.C., Akilesh S., Jung N., et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 170 7 (2003) 3528-3533
41. Hinton P.R., Xiong J.M., Johlfs M.G., Tang M.T., Keller S., and Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 176 1 (2006) 346-356
42. Ober R.J., Radu C.G., Ghetie V., and Ward E.S. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13 12 (2001) 1551-1559
43. Ghetie V., and Ward E.S. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 18 (2000) 739-766
44. Yoshida M., Claypool S.M., Wagner J.S., Mizoguchi E., Mizoguchi A., Roopenian D.C., et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20 6 (2004) 769-783
45. Sasaki T., and Yonemasu K. Chemical studies on the isolated collagen-like and globular fragment of complement component C1q Comparative studies on bovine and human C1q. Biochim Biophys Acta 742 1 (1983) 122-128
46. Reid K.B., Gagnon J., and Frampton J. Completion of the amino acid sequences of the A and B chains of subcomponent C1q of the first component of human complement. Biochem J 203 3 (1982) 559-569
47. Muir R. On the relationships between the complements and immune bodies of different animals. J Pathol Bacteriol 16 (1911) 523
48. Morgan B.P., Berg C.W., and Harris C.L. "Homologous restriction" in complement lysis: roles of membrane complement regulators. Xenotransplantation 12 4 (2005) 258-265
49. Cohen-Solal J.F., Cassard L., Fridman W.H., and Sautes-Fridman C. Fc gamma receptors. Immunol Lett 92 3 (2004) 199-205
50. Nimmerjahn F., and Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 24 1 (2006) 19-28
51. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 3 (2002) 754-758
52. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64 13 (2004) 4664-4669
53. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 21 (2003) 3940-3947
54. Ternant D., Ohresser M., Thomas C., Cartron G., Watier H., and Paintaud G. Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies. Blood 106 4 (2005) 1503-1504 [author reply 1504-5]
55. Carter D.L., Shieh T.M., Blosser R.L., Chadwick K.R., Margolick J.B., Hildreth J.E., et al. CD56 identifies monocytes and not natural killer cells in rhesus macaques. Cytometry 37 1 (1999) 41-50
56. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 2 (1994) 435-445
57. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 4 (2000) 443-446
58. Self C.H., and Thompson S. How specific are therapeutic monoclonal antibodies?. Lancet 367 9516 (2006) 1038-1039